LINC01559 accelerates pancreatic cancer cell proliferation and migration through YAP‐mediated pathway

Abstract

Pancreatic cancer (PC) is one of the top two most fatal cancers, with the poorest survival rate among all human malignancies. Increasing evidence suggests the involvement of long noncoding RNAs (lncRNAs) in the initiation and progression of various cancers. Herein, we investigated the role of lncRNA LINC01559 in PC.Several online databases indicated that LINC01559 was at a low expression in normal pancreatic tissues but was obviously upregulated in PAAD tissues. Further, our results showed that LINC01559 was stimulated in PC cell lines relative to normal controls. Furthermore, we validated that LINC01559 facilitated PC cell proliferation and migration in vitro. Also, silencing LINC01559 obstructed PC cell growth in vivo.Besides, LINC01559 was revealed to be mainly in the cytoplasm of PC cells and therefore served as a ceRNA of Yes-associated protein (YAP) in PC cells via sponging miR-607. Surprisingly, we also proved that LINC01559 could interact with YAP protein, which might hinder YAP phosphorylation and enhance YAP transcriptional activity in PC cells. Furthermore, we demonstrated that YAP was the downstream effector in LINC01559-regulated PC development. Collectively, our findings unmasked that LINC01559 accelerates PC progression through relying on YAP, providing a new potential target for clinical treatment of patients with PC.

Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer

“…LINC01559 has been identified as a potential non-invasive biomarker of renal cell carcinoma and is reported to accelerate pancreatic cancer cell proliferation and invasion through enhancing YAP activity, and UNC5B-AS1 is associated with tumourigenesis and metastasis of papillary thyroid cancer [21,23,34]. Our results suggest that LINC01559 and UNC5B-AS1 are novel regulators of aerobic glycolysis in PDAC.…”

“…Moreover, FEZF1-AS1 has been demonstrated to promote the glycolytic phenotypes of colorectal cancer by regulating PKM2 signaling [18]. From the therapeutic point of view, we therefore verified the roles of LINC01559 and UNC5B-AS1, which have been implicated in several oncogenic processes but not involved in glycolysis [19][20][21][22][23]. Data from the TCGA + GTEx portal showed that LINC01559 and UNC5B-AS1 were highly expressed in the tumor tissues (n = 179) compared with normal pancreas samples (n = 171) ( Fig.…”

Identification of Ten Long Noncoding RNAs as Biomarkers for Hepatocellular Carcinoma

“…LINC02154 is risk factor for laryngeal cancer. LINC01559 accelerates pancreatic cancer cell proliferation and migration [28]. The co-expression network and function of these 10 lncRNAs were analyzed.…”

Research progress on long non-coding RNAs and their roles as potential biomarkers for diagnosis and prognosis in pancreatic cancer

“…This can in turn promote tumorigenesis [ 36 ]. LINC01559 was believed to play various roles in modulation of the YAP signaling pathways in the cytoplasm of pancreatic cancer cells [ 37 ]. In one mechanism, LINC01559 can act as a miRNA sponge of miR-607 to upregulate the expression of YAP1.…”

“…In one mechanism, LINC01559 can act as a miRNA sponge of miR-607 to upregulate the expression of YAP1. In an additional mechanism, LINC01559 can also directly bind to YAP1 and block its phosphorylation, thereby promoting its activation [ 37 ]. A similar role was also discovered for lncRNA THAP9 antisense RNA 1, which not only sponges miR-484, but also directly binds to YAP1 and inhibits phosphorylation-mediated inactivation by large tumor suppressor gene 1.…”